Nordic ORgan Preservation Pilot Approach Nonrandomised Single-Arm Trial for Non-Operative Management of Rectal Cancer
Key facts
- Where
- Helsinki, Jyväskylä, Kuopio, Oulu, Pori, Seinäjoki, Tampere, Turku és Vaasa, FinnországSee the 9 sites
Where in Finnország
- Helsinki University Central HospitalHelsinki, FinnországTaking people
- Jyväskylä Central HospitalJyväskylä, FinnországTaking people
- Kuopio University HospitalKuopio, FinnországTaking people
- Oulu University HospitalOulu, FinnországTaking people
- Satakunta Central HospitalPori, FinnországTaking people
- Seinäjoki Central HospitalSeinäjoki, FinnországTaking people
- Tampere University HospitalTampere, FinnországTaking people
- Turku University HospitalTurku, FinnországTaking people
- Vaasa Central HospitalVaasa, FinnországTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tampere University Hospital
- Trial code
- NCT06328361
- Record updated
- 2026. szeptember 30.
- Original description
The goal of this one-arm clinical trial is to implement and study the oncological outcomes of nonoperative management of rectal cancer having complete clinical response to neoadjuvant therapy. The main questions to answer areRead full original descriptionShow less
Nordic ORgan Preservation Pilot Approach - A Nonrandomised Single-Arm Trial for Non-Operative Management of Rectal Cancer (NORPPA-1)
The goal of this one-arm clinical trial is to implement and study the oncological outcomes of nonoperative management of rectal cancer having complete clinical response to neoadjuvant therapy. The main questions to answer are
* if the oncological results of nonoperative management after Nordic practice in chemoradiotherapy indications differ from experiences elsewhere * what is the organ preservation rate * what is the local regrowth rate
Inclusion: Histopathological verification of primary rectal adenocarcinoma; Complete clinical response at response assessment after neoadjuvant therapy; Informed consent to organ preservation study.
Exclusion: No neoadjuvant therapy; Evidence of metastatic disease (fulfilling M-class criteria of TNM); Inability to understand the information related to harms and benefits.